A preparation method for spray-dried powder for improving the hygroscopicity of a Ganoderma spore powder polysaccharide and a use of the spray-dried powder. The method comprises the following steps: A, extracting a Ganoderma polysaccharide to obtain a Ganoderma polysaccharide extracted solution; B, concentrating the Ganoderma polysaccharide extracted solution to obtain a Ganoderma polysaccharide concentrated solution; and C, mixing the Ganoderma polysaccharide concentrated solution with a drying aid, and then carrying out spray drying treatment to obtain a Ganoderma spore powder polysaccharide spray-dried powder.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 31/00 - Extraits ou préparations comestibles de champignonsLeur préparation ou leur traitement
A23L 29/00 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement
F26B 21/00 - Dispositions pour l'alimentation ou le réglage de l'air ou des gaz pour le séchage d'un matériau solide ou d'objets
C08L 5/00 - Compositions contenant des polysaccharides ou leurs dérivés non prévus dans les groupes ou
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
The present invention relates to the technical field of quality standards and measurement of health-care food. Disclosed is a method for measuring content of multiple lipid components in Ganoderma lucidum spore oil by quantitative analysis of multi-components by single marker. According to the present invention, high-performance liquid chromatography is used, glycerol trioleate is used as an internal standard, correction factors for glycerol trioleate and other lipid components are established, and the correction factors are used to calculate the concentrations of multiple components to be measured in lipids in Ganoderma lucidum spore oil. According to the present invention, in the high-performance liquid chromatography, acetonitrile-acetone-isooctane is used as a mobile phase, and HPLC-UV combination has strong specificity.
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A23P 10/28 - Mise en comprimésFabrication de produits alimentaires en barres par compression d’un mélange pulvérulent sec
A23L 29/30 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sirops d'hydrate de carboneAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sucresAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des alcools de sucre, p. ex. du xylitolAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des hydrolysats d'amidon, p. ex. de la dextrine
A23L 29/00 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement
4.
EGG YOLK PHOSPHOLIPID COMPOSITION HAVING GOOD OXIDATION STABILITY AND USE
An egg yolk phospholipid composition having good oxidation stability and a preparation method therefor. In the composition, the mass of phospholipid accounts for 30%-40% of the total mass, and protein accounts for 60%-70% of the total mass. The preparation method comprises the following steps: A, separately weighing a phospholipid product and a protein product, such that the mass of phospholipid accounts for 30%-40% of the total mass; and B, uniformly mixing the phospholipid product with the protein product.
A ganoderma lucidum spore powder tablet and a preparation method thereof, the tablet comprising ganoderma lucidum spore powder and sargassum polysaccharide, the method comprising the following steps: (A) performing ultrafine-grinding the ganoderma lucidum spore powder to prepare wall-broken ganoderma lucidum spore powder; (B) weighing the wall-broken ganoderma lucidum spore powder and sargassum polysaccharide in proportion; (C) mixing the materials; and (D) performing granulating, sieving, drying, and tableting.
A23L 31/00 - Extraits ou préparations comestibles de champignonsLeur préparation ou leur traitement
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A23L 29/30 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sirops d'hydrate de carboneAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sucresAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des alcools de sucre, p. ex. du xylitolAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des hydrolysats d'amidon, p. ex. de la dextrine
A23P 10/28 - Mise en comprimésFabrication de produits alimentaires en barres par compression d’un mélange pulvérulent sec
6.
METHOD FOR SIMULTANEOUSLY PREPARING HIGH-PURITY SPHINGOMYELIN AND GLYCEROL PHOSPHOCHOLINE
Disclosed in the present invention is a method for simultaneously preparing high-purity sphingomyelin and glycerol phosphocholine. The method comprises the following steps: 1) adding a degradation agent to a phospholipid mixture to degrade phospholipid, so as to obtain a sphingomyelin and glycerol phosphocholine mixture, and carrying out separation by means of a refining method to obtain a crude product; 2) carrying out column chromatography to obtain sphingomyelin having a purity higher than 98%; and 3) obtaining glycerol phosphocholine having a purity higher than 95% by means of a refining method; and 4) drying same to obtain a phospholipid satisfying the pharmaceutical standard. The solvent used in the present invention can be recycled and reused and is environmentally friendly, and the method has mild reaction conditions, good selectivity, low requirement for the raw material purity, and a relatively low production cost, and is beneficial to industrial mass production.
Provided in the present disclosure is a preparation method of paeoniflorin-6′-O-benzene sulfonate. The method uses crude paeoniflorin instead of paeoniflorin as a raw material, which more complies with actual requirements of an industrial production process of paeoniflorin-6′-O-benzene sulfonate, and uses an organometallic catalyst, an acid-binding agent and chemically active benzenesulfonyl chloride to react with paeoniflorin. Compared with the prior art, the method significantly increases the yield of crude paeoniflorin-6′-O-benzene sulfonate which is separated and purified by means of column chromatography and then refined to obtain paeoniflorin-6′-O-benzenesulfonate with a content of at least 98%, thereby realizing industrial production of the paeoniflorin-6′-O-benzene sulfonate.
A method for preparing a Ganoderma lucidum spore oil oral liquid with improved mouthfeel, which is characterized by comprising the following steps: A. mixing an antioxidant, a Ganoderma lucidum spore oil, and an emulsifier, and stirring until completely dissolved and uniform to form an oil phase; B. heating water and maintaining the temperature to form a water phase; C. adding the oil phase to the water phase and stirring under high-speed shear to prepare a preliminary emulsion A; D. adding a pH adjuster to the preliminary emulsion A and performing ultrasonic treatment to prepare a preliminary emulsion B; E. homogenizing the preliminary emulsion B to obtain a final emulsion; and F. performing filling and sterilizing on the final emulsion to obtain the Ganoderma lucidum spore oil oral liquid with improved mouthfeel. The obtained oral liquid comprises components in the following mass proportions: the Ganoderma spore oil at 5-25%, the emulsifier at 0.5-20%, the antioxidant at 0.01-0.05%, and the pH adjuster at 0.001-0.01%, the balance being water.
Ganoderma lucidum spore oil and use thereof in the preparation of anti-cancer-related fatigue medicaments are provided. The content of triglycerides in the Ganoderma lucidum spore oil is greater than 90%. Ganoderma lucidum triterpenoids are not detected. The Ganoderma lucidum spore oil is extracted by means of supercritical CO2, eluted with a silica gel column and a mixed solution of petroleum ether-ethyl acetate, concentrated under reduced pressure and vacuum-dried. The Ganoderma lucidum spore oil is highly effective in mitigating cancer-related fatigue, has good safety, and can be used in the preparation of medicaments for treating cancer-related fatigue.
The present invention relates to the field of synthetic phospholipids. Disclosed is a method for simultaneously preparing specific phosphatidylcholine and phosphatidylethanolamine. The method comprises the following steps: adding an amino protective group into a phospholipid mixture, degrading phospholipids by using sodium alkoxide to obtain a mixture of glycerylphosphorylcholine and glycerylphosphorylethanolamine, refining the mixture by using a mixed solvent, and reacting with a specific fatty acid to generate specific synthetic phosphatidylcholine and phosphatidylethanolamine; carrying out column chromatography to respectively obtain phospholipids having a purity of 98% or higher; and carrying out freeze drying to obtain phospholipids conforming to medicinal standards. According to the present invention, solvents used all can be recycled, and are environmentally friendly, reaction conditions are mild, the selectivity is good, the requirement on the purity of raw materials is low, the production cost is relatively low, and industrial mass production is facilitated.
The present invention belongs to the field of compounds, and discloses a method for preparing albiflorin-6'-O-benzenesulfonate. The method comprises the following steps: taking a medicinal material that is rich in albiflorin as a starting material, subjecting same to extraction, adsorption, separation and purification to obtain albiflorin with a relatively high purity; and reacting an organic metal catalyst, an acid-binding agent and chemically active benzenesulfonyl chloride with albiflorin, carrying out column chromatography separation and refining on the product to obtain more than 98% of albiflorin-6'-O-benzenesulfonate, dissolving same in a mixed solvent, and carrying out programmed drying to finally obtain a finished product of albiflorin-6'-O-benzenesulfonate. The method has a high reaction yield, a simple operation, and mild conditions, and is very suitable for industrial production of albiflorin-6'-O-benzenesulfonate.
Use of ganoderma lucidum spore oil in preparing a drug for prolonging the survival time of tumor patients. The ganoderma lucidum spore oil has the effect of prolonging the survival time of tumor-bearing mice and is used for preparing the drug for prolonging the survival time of tumor patients.
The present invention relates to the technical field of pharmaceutical chemistry, in particular to a 8-debenzoylpichlorin-6'-O-benzenesulfonate, a preparation method therefor, and the use thereof in treating Sjögren's syndrome and rheumatoid arthritis. The preparation method comprises: taking paeoniflorin-6'-O-benzenesulfonate as a raw material, performing hydrolysis, extraction and column chromatography, and then performing liquid phase separation so as to obtain the product. The 8-debenzoylpaeoniflorin-6'-O-benzenesulfonate of the present invention has a higher bioavailability than those of paeoniflorin and paeoniflorin-6'-O-benzenesulfonate, has a significant therapeutic effect on Sjögren's syndrome and rheumatoid arthritis, and can be prepared as a medicine for treating Sjögren's syndrome and rheumatoid arthritis.
A ternary solvent drying method for paeoniflorin-6'-O-benzene sulfonate, comprising the following steps: dissolving paeoniflorin-6'-O-benzene sulfonate in a mixed solvent, and carrying out programmed drying. The mixed solvent contains dimethyl carbonate, C3-C4 ketone, and water at a specific ratio. The drying method can reduce the residual solvent on paeoniflorin-6'-O-benzene sulfonate, maintains the stability of paeoniflorin-6'-O-benzene sulfonate while ensuring that the residual solvent on a paeoniflorin-6'-O-benzene sulfonate finished product is up to standard, has the contents of related substances not increased obviously, ensures the quality of the paeoniflorin-6'-O-benzene sulfonate finished product, and is applicable for industrial production of paeoniflorin-6'-O-benzene sulfonate.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
15.
METHOD FOR PREPARING PAEONIFLORIN-6-O'-BENZENE SULFONATE
Provided in the present invention is a method for preparing paeoniflorin-6-O'-benzene sulfonate. The method uses crude paeoniflorin instead of paeoniflorin as a raw material, which more complies with actual requirements of an industrial production process of paeoniflorin-6-O'-benzene sulfonate, and uses an organic metal catalyst, an acid-binding agent and chemically active benzenesulfonyl chloride to react with paeoniflorin. Compared with the prior art, the method significantly increases the yield of crude paeoniflorin-6-O'-benzene sulfonate which is separated and purified by means of column chromatography and then refined to obtain paeoniflorin-6-O'-benzenesulfonate with a content of at least 98%, thereby realizing industrial production of the paeoniflorin-6-O'-benzene sulfonate.
A ganoderma spore oil and a use thereof in the preparation of a drug for counteracting cancer-related fatigue. The content of triglyceride components in the ganoderma spore oil is greater than 90%. Ganoderma triterpenoid compounds are not detected. The ganoderma spore oil is extracted by means of supercritical CO2, eluted with a silica gel column and a petroleum ether-ethyl acetate mixed solution, concentrated under reduced pressure and vacuum-dried. The ganoderma spore oil is highly effective in mitigating cancer-related fatigue, has good safety, and can be used in the preparation of a drug for treating cancer-related fatigue.
The present invention provides a purification method for paeoniflorin-6-O'-benzene sulfonate. According to the purification method, the purification process for paeoniflorin-6-O'-benzene sulfonate can be reduced, and impurities, such as benzenesulfonyl chloride and derivatives thereof, iron, and heavy metals, in the prepared paeoniflorin-6-O'-benzene sulfonate crude product can be effectively removed, to obtain paeoniflorin-6-O'-benzene sulfonate of which the content is 98% or more. In addition, under the condition of ensuring high content, the energy consumption is low, the solvent dosage is small, the time consumption is low, and the method is thus suitable for industrial production of paeoniflorin-6-O'-benzene sulfonate.
Provided in the present invention is a method for synthesizing a paeoniflorin derivative of formula III. The synthesis method can obviously reduce the use amount of a reaction solvent, shortens the reaction time, has the characteristics of saving on cost, simple operation, mild conditions and greatly improved reaction yield, is suitable for a more extensive paeoniflorin structural modification, and can meet the needs of industrialization.
C07H 1/00 - Procédés de préparation des dérivés du sucre
C07H 17/04 - Radicaux hétérocycliques contenant uniquement des atomes d'oxygène comme hétéro-atomes du cycle
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
19.
HESPERETIN EMULSION AND PREPARATION METHOD THEREFOR
A hesperetin emulsion and a preparation method therefor. The hesperetin emulsion comprises the following components in percentages by mass: 0.3-3% of hesperetin, 10-30% of an oil phase solvent, 3.0-20% of an emulsifier, 0.03-0.6% of a stabilizer, and 1-5% of an isoosmotic adjusting agent, and further comprises a pH regulator, a hesperetin solubilizer, and the balance being water for injection, wherein the pH value of the emulsion is 7.0-8.5. The emulsion improves the drug-loading capacity of hesperetin and improves the problem of rapid metabolization due to oral absorption.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
20.
METHOD FOR ACCURATELY CONTROLLING CONTENT OF PALMITIC ACID IN OLIVE OIL
The present invention relates to the technical field of medicinal oil refining. Disclosed is a method for accurately controlling content of palmitic acid in olive oil. The method uses virgin olive oil as a raw material, and uses a mixed filler formed by lipase, inorganic base, a filtering aid, an adsorbent, and the like to remove impurities to prepare olive oil having a low palmitic acid content instead of conventional enzyme hydrolysis, de-acidification and impurity removal processes. The present invention is characterized in that the content of palmitic acid in olive oil is accurately controlled within a specific range of 7.5-12% by means of one-step treatment, and industrial production can be achieved.
C11B 3/06 - Raffinage des graisses ou huiles par réaction chimique avec des bases
C11B 3/10 - Raffinage des graisses ou huiles par adsorption
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
21.
METHOD FOR PRECISELY CONTROLLING CONTENT OF STEARIC ACID IN SOYBEAN OIL USING MIXED FILLER
The present invention relates to the technical field of pharmaceutically acceptable oil refining. Disclosed is a method for precisely controlling the content of stearic acid in soybean oil using a mixed filler. The method comprises the following steps: A. uniformly mixing a lipase, an inorganic base, a filter aid, and an adsorbent in physical fashion to form a mixed filler, wherein the lipase is a Sn-1,3 specific lipase; and B. causing soybean oil to flow through the mixed filler to obtain refined soybean oil. The present invention solves the problem that conventional soybean oil production processes cannot accurately control the content of stearic acid and cannot meet the requirements of preparing high-quality lipid emulsion formulations.
C11B 3/06 - Raffinage des graisses ou huiles par réaction chimique avec des bases
C11B 3/10 - Raffinage des graisses ou huiles par adsorption
C12P 7/64 - GraissesHuilesCires de type esterAcides gras supérieurs, c.-à-d. ayant une chaîne continue d'au moins sept atomes de carbone liée à un groupe carboxyleHuiles ou graisses oxydées
22.
EMULSION STABILIZER AND NUTRITION EMULSION COMPRISING SAME
An emulsion stabilizer and a nutrition emulsion comprising same. The emulsion stabilizer contains 90-95% of a phospholipid, 1-5% of a monoglyceride and a diglyceride, and 1-5% of a lauric acid monoglyceride. In addition, also disclosed is a method for preparing a total nutrition powder for special medical use comprising the emulsion stabilizer. The emulsion stabilizer can improve the stability and uniformity of the emulsion during the preparation of the total nutrition powder, and mitigate the phenomenon of fat floating after homogenization, so that the emulsion can still be restored by oscillation after centrifugation, and will not be stratified after standing for 10 hours, ensuring the stability of the emulsion before homogenization to spray drying during the preparation of the total nutrition powder. The total nutrition powder formula has reasonable and comprehensive nutrition matching.
A drug for combating tumor multi-drug resistance, which comprises a Ganoderma lucidum extract, the Ganoderma lucidum extract being obtained by means of performing extraction by using alcohol.
brevets
